Ryan Savitz sold $9.5M of DNTH
EVP, CFO & CBO at Dianthus Therapeutics, Inc. /DE/. 114,367 shares at an average of $83.00, traded Mar 31, 2026, filed Apr 1, 2026.
Score components
- +22RoleCFO
- +25Trade size$9.5M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.4%, 3m +6.7%, 6m +4.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001992324-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | MOption exercise Common Stock10b5-1 | +74,367 | $8.44 | $628k | 74,367 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Common Stock10b5-1 | +40,000 | $17.88 | $715k | 114,367 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -1,390 | $78.33 | $109k | 112,977 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -21,825 | $78.86 | $1.7M | 91,152 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -1,485 | $80.25 | $119k | 89,667 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $81.36 | $65k | 88,867 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -2,366 | $82.84 | $196k | 86,501 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -59,800 | $83.90 | $5.0M | 26,701 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -19,469 | $84.57 | $1.6M | 7,232 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -7,232 | $85.54 | $619k | 0 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -74,367 | $0.00 | $0 | 10,399 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 80,000 | Apr 1, 2026 |
Related signals
Other insiders at Dianthus Therapeutics, Inc. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Edward Carr CHIEF ACCOUNTING OFFICER | $2.0M 20,000 shares | -100% | |
| 33Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.5M 23,124 shares | -85% | |
| 30Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $327k 2,778 shares | -100% | |
| 29Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $304k 2,777 shares | -100% | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.2M 20,000 shares | -522% | |
| 38Weak | Dianthus Therapeutics, Inc. /DE/ | Anne McGeorge director | $845k 7,750 shares | -100% | |
| 50Moderate | Dianthus Therapeutics, Inc. /DE/ | Marino Garcia CEO AND PRESIDENT | $18M 166,000 shares | -72% | |
| 32Weak | Dianthus Therapeutics, Inc. /DE/ | Ryan Savitz EVP, CFO & CBO | $3.2M 31,249 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.4M 30,000 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.4M 26,530 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.